Renal impairment Venous thromboembolism Nierinsufficiëntie Veneuze trombo-embolie
Conditions
Interventions
One venous blood sample
Sponsors
Medisch Centrum Leeuwarden
Eligibility
Inclusion criteria
Inclusion criteria: - Age at least 18 years - Therapeutic dose of Fraxiparine or Fraxodi - Subcutaneous nadroparin administration for at least three days - Written informed consent
Exclusion criteria
Exclusion criteria: - Use of nadroparin before hospital admission - Patients known for heparin resistance - Patients on hemodialysis - Use of antifactor Xa inhibitors other than nadroparin (all remaining LMWHs, dabigatran, apixaban, rivaroxaban, heparin and fondaparinux) within 7 days before the start of the study or during the study - Use of Cofact or Beriplex within 7 days before the start or during the study
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| - The mean anti-Xa activity in patients with an eGFR 60 ml/min. - The percentage of patients with an eGFR 60 ml/min, obtaining an adequate anti-Xa activity. - The percentage of patients with an eGFR 60 ml/min, obtaining an adequate anti-Xa activity. - The number of patients with an eGFR 60 ml/min experiencing a trombo-embolic event or bleeding complication during hospital admission. - The number of patients with an eGFR 60 ml/min experiencing a trombo-embolic event during hospital admission. -The number of patients with an eGFR 60 ml/min experiencing a bleeding complication during hospital admission. | — |
Primary
| Measure | Time frame |
|---|---|
| The mean anti-Xa activity in patients with an eGFR 60 ml/min treated with therapeutic doses of nadroparin. | — |
Contacts
Public ContactA.L. van Ojik
Medisch Centrum Leeuwarden, Department of Clinical Pharmacy & Pharmacology, P.O. Box 888
Outcome results
None listed